Company: MLTX
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001140361-25-014923
Chunk: 10

Company: MoonLake Immunotherapeutics
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 10
---
 for a term expiring at the 2028 Annual General Meeting of Shareholders; one Class I director, whose term expires at the 2026 Annual General Meeting of Shareholders; and two Class II directors, whose terms expire at the 2027 Annual General Meeting of Shareholders. Biographical and other information regarding our director nominees and directors continuing in office, including the primary skills and experiences considered by our Nominating and Corporate Governance Committee (the “Nominating Committee”) in determining to recommend them as nominees, is set forth below.

| Name                       |     | Class |     |              Age 
 (as of April 22) |     | Position                             |
| Dr. Jorge Santos da Silva  |     | III   |     |               48 |     | Chief Executive Officer; Director    |
| Simon Sturge(1)(3)         |     | III   |     |               66 |     | Independent Chairperson of the Board |
| Spike Loy(1)(2)            |     | I     |     |               44 |     | Independent Director                 |
| Catherine Moukheibir(1)(2) |     | II    |     |               65 |     | Independent Director                 |
| Dr. Andrew Phillips(2)(3)  |     | III   |     |               54 |     | Independent Director                 |
| Dr. Ramnik Xavier          |     | II    |     |               63 |     | Independent Director                 |

| (1) | Member of the Audit Committee |

| (2) | Member of the Compensation Committee |

| (3) | Member of the Nominating Committee |

Class I Director Continuing in Office Spike Loy has served as a director of our Company since April 2022. Mr. Loy has also served as a director of our subsidiary, MoonLake AG, since May 2021. Mr. Loy is a Managing Director at BVF Partners L.P., a private investment firm, where he has served since August 2009. Mr. Loy previously served as a director of GH Research PLC (Nasdaq: GHRS), a biopharmaceutical company, from October 2020 to March 2022, and currently serves as a director of multiple private biopharmaceutical companies. Mr. Loy holds a J.D. from Harvard Law School and a B.A. in Human Biology, with a minor in Economics, from Stanford University. We believe Mr. Loy is qualified to serve on our Board because